New drug aims to limit heart damage after a heart attack

NCT ID NCT07362446

First seen Feb 01, 2026 · Last updated May 14, 2026 · Updated 19 times

Summary

This study tests a medicine called Xolatryp in 300 adults who have had a severe heart attack (STEMI) and are getting a procedure to open blocked arteries. Participants receive either a single 6-hour infusion of Xolatryp or a placebo (no active drug). The goal is to see if Xolatryp is safe and helps the heart recover better. The study lasts about 30 days.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYOCARDIAL INFARCTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Liverpool Hospital

    NOT_YET_RECRUITING

    Liverpool, New South Wales, 2170, Australia

  • Nepean Hospital

    RECRUITING

    Kingswood, New South Wales, 2747, Australia

  • Northern Health

    NOT_YET_RECRUITING

    Epping, Victoria, 3076, Australia

  • Royal Adelaide Hospital

    NOT_YET_RECRUITING

    Adelaide, South Australia, 5000, Australia

  • Sir Charles Gairdner Hospital

    NOT_YET_RECRUITING

    Nedlands, Western Australia, 6009, Australia

  • Sunshine Hospital

    NOT_YET_RECRUITING

    Saint Albans, Victoria, 3021, Australia

Conditions

Explore the condition pages connected to this study.